These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 9257427)

  • 1. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.
    Osoba D; Zee B; Warr D; Latreille J; Kaizer L; Pater J
    Support Care Cancer; 1997 Jul; 5(4):307-13. PubMed ID: 9257427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.
    Osoba D; Zee B; Pater J; Warr D; Latreille J; Kaizer L
    J Clin Oncol; 1997 Jan; 15(1):116-23. PubMed ID: 8996132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy.
    Rusthoven JJ; Osoba D; Butts CA; Yelle L; Findlay H; Grenville A
    Support Care Cancer; 1998 Jul; 6(4):389-95. PubMed ID: 9695208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.
    Jordan K; Grothey A; Kegel T; Fibich C; Schöbert C
    Onkologie; 2005 Feb; 28(2):88-92. PubMed ID: 15662112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring chemotherapy-induced nausea and emesis.
    Martin CG; Rubenstein EB; Elting LS; Kim YJ; Osoba D
    Cancer; 2003 Aug; 98(3):645-55. PubMed ID: 12879484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life studies in chemotherapy-induced emesis.
    Osoba D; Zee B; Warr D; Kaizer L; Latreille J; Pater J
    Oncology; 1996 Jun; 53 Suppl 1():92-5. PubMed ID: 8692559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The development of a new QOL Questionnaire on chemotherapy - induced emesis and vomiting--investigation of reliability and validity. Group for Investigation of QOL Questionnaire for Anti-Emetics Used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative study].
    Ishihara Y; Nukariya N; Kobayashi K; Yoneda S; Matsuda T; Yakushiji M; Yamakido M; Fukuoka M; Niitani H; Furue H
    Gan To Kagaku Ryoho; 1996 May; 23(6):745-55. PubMed ID: 8645026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
    Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
    J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting.
    Jordan K; Grothey A; Pelz T; Lautenschläger C; Franke U; Schöber C; Schmoll HJ
    Eur J Cancer Care (Engl); 2010 Sep; 19(5):603-9. PubMed ID: 19725867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of an anti-emetic tropisetron capsule on QOL of patients with delayed nausea and vomiting induced by cancer chemotherapy. Group for Investigation of QOL Questionnaire for Anti-Emetics used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative Study].
    Nukariya N; Kobayashi K; Ishihara Y; Yoneda S; Matsuda T; Yakushiji M; Yamakido M; Fukuoka M; Niitani H; Furue H
    Gan To Kagaku Ryoho; 1996 May; 23(6):757-71. PubMed ID: 8645027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer.
    Perwitasari DA; Atthobari J; Mustofa M; Dwiprahasto I; Hakimi M; Gelderblom H; Putter H; Nortier JW; Guchelaar HJ; Kaptein AA
    Int J Gynecol Cancer; 2012 Jan; 22(1):139-45. PubMed ID: 22080888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
    Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W
    Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.
    Treish I; Shord S; Valgus J; Harvey D; Nagy J; Stegal J; Lindley C
    Support Care Cancer; 2003 Aug; 11(8):516-21. PubMed ID: 12836088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life consequences of chemotherapy-induced emesis.
    Lindley CM; Hirsch JD; O'Neill CV; Transau MC; Gilbert CS; Osterhaus JT
    Qual Life Res; 1992 Oct; 1(5):331-40. PubMed ID: 1299465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.
    Escobar Y; Cajaraville G; Virizuela JA; Álvarez R; Muñoz A; Olariaga O; Tamés MJ; Muros B; Lecumberri MJ; Feliu J; Martínez P; Adansa JC; Martínez MJ; López R; Blasco A; Gascón P; Calvo V; Luna P; Montalar J; Del Barrio P; Tornamira MV
    Support Care Cancer; 2015 Sep; 23(9):2833-40. PubMed ID: 26081597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
    J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.